Drugs / MEDI-565
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01284231 | Dec 2010 → Jan 2015 | adenocarcinoma | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-565 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01284231 ↗ |
| Route | Intravenous | “MEDI-565 will be administered by IV infusion” NCT01284231 ↗ |
| Target | CD3E | “T-cell surface glycoprotein CD3 epsilon chain cross-linking agent” CHEMBL2109372 ↗ |
| Target | CEACAM5 | “Carcinoembryonic antigen-related cell adhesion molecule 5 cross-linking agent” CHEMBL2109372 ↗ |